<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989725</url>
  </required_header>
  <id_info>
    <org_study_id>Suppress-HNC</org_study_id>
    <nct_id>NCT04989725</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and Neck Cancer</brief_title>
  <acronym>Suppress-HNC</acronym>
  <official_title>Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and Neck Cancer: A Phase II Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A registry-based randomized phase II trial. A total of 46 patients with metastatic head and&#xD;
      neck cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be&#xD;
      randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best&#xD;
      supportive care, continue current systemic line, based on treating physician decision) vs.&#xD;
      receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing&#xD;
      their current systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized screening phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>PFS defined from randomization to disease progression at any site or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>OS defined as time from randomization to time of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Measured using the FACT-G tool, head and neck cancer-related patient reported outcome- CTCAE (PRO-CTCAE) and Quality of life 5-level EQ-5D</measure>
    <time_frame>5 years</time_frame>
    <description>Measured using the FACT-G tool, lung cancer-related patient reported outcome- CTCAE (PRO-CTCAE) and quality of life 5-level EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 toxicity Measured using the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</measure>
    <time_frame>5 years</time_frame>
    <description>Measured using the Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as time from the end of SABR treatment to date of local failure and will be measured only in the experimental arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next systemic therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as time from randomization to time of subsequent therapy line</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Oligoprogressive</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switch to subsequent systemic therapy line, best supportive care or continue current systemic line</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental SABR arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Definitive SABR to oligoprogressive lesions + continue current systemic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard arm</intervention_name>
    <description>Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>SABR to all oligoprogressive lesions + continuation of current systemic therapy</description>
    <arm_group_label>Experimental SABR arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Biopsy proven HNSCC (oropharynx, oral cavity, nasopharynx, sinonasal, larynx or&#xD;
             hypopharynx)&#xD;
&#xD;
          -  Metastatic HNSCC, with pathological or radiological proof of metastasis&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Progressive disease while on systemic treatment (any line), defined as per RECIST&#xD;
             criteria 1.1 on CT metrics as a greater than 20% increase in the sum measurement of&#xD;
             lesions, non-target unequivocal progressive disease or a new lesion on CT.&#xD;
&#xD;
          -  Oligoprogression to 1-5 extracranial lesions ≤ 5cm and involving ≤ 3 organs.&#xD;
             Progression at the primary tumor site should be counted within the total of 5 lesions.&#xD;
             For patients with lymph node metastases, each node is counted as one site of&#xD;
             metastasis.&#xD;
&#xD;
          -  All sites of disease can, in the opinion of the investigator, be safely treated and&#xD;
             targetable with SABR (taking into account prior local therapy, organ function and&#xD;
             underlying medical condition such as inflammatory bowel disease, pulmonary fibrosis,&#xD;
             etc.)&#xD;
&#xD;
          -  Patients with prior metastases that have been treated with ablative therapies (e.g.&#xD;
             radiotherapy, surgery or radiofrequency ablation) before their current line of&#xD;
             systemic therapy, are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Any medical condition that could, in the opinion of the investigator, preclude&#xD;
             radiotherapy or prevent follow-up after radiotherapy.&#xD;
&#xD;
          -  Presence of spinal cord compression&#xD;
&#xD;
          -  Metastatic disease that invades the GI tract (including esophagus, stomach, small or&#xD;
             large bowel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvine Benth</last_name>
    <phone>514-890-8254</phone>
    <email>silvine.benth.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mom Phat</last_name>
    <phone>514-890-8254</phone>
    <email>mom.phat.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvine Benth</last_name>
      <phone>514-890-8254</phone>
      <email>silvine.benth.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Houda Bahig, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Soulières, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>metastatic cancer</keyword>
  <keyword>oligoprogression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

